Avastin: all it's cracked up to be?
Last year, Philip Rosenfeld of the Bascom Palmer Eye Institute in Miami, USA, announced some findings that made the ophthalmology community stand to attention. He claimed that intravitreal administration of the cancer agent, Avastin (bevacizumab), in wet age-related macular degeneration (AMD) patients yielded very positive results. Since then, industry journals have been inundated with reports of the benefits of this agent in an ophthalmic setting.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Recent Videos
Related Content
